Biocon’s subsidiary -- Biocon Biologics has received marketing authorization approval from the European Commission (EC) for Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. The company has received approval following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Abevmy 100 & 400 mg, a biosimilar Bevacizumab, is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, nonsmall-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
